Adc Therapeutics SA (NYSE: ADCT) is -3.52% lower on its value in year-to-date trading and has touched a low of $1.71 and a high of $6.04 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ADCT stock was last observed hovering at around $2.00 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $1.92, the stock is -7.76% and -19.38% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.39 million and changing -4.00% at the moment leaves the stock -40.63% off its SMA200. ADCT registered 0.00% loss for a year compared to 6-month loss of -39.05%. The firm has a 50-day simple moving average (SMA 50) of $2.4022 and a 200-day simple moving average (SMA200) of $3.24715.
The stock witnessed a -38.66% gain in the last 1 month and extending the period to 3 months gives it a -37.46%, and is -3.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.03% over the week and 13.42% over the month.
Adc Therapeutics SA (ADCT) has around 162 employees, a market worth around $185.64M and $70.72M in sales. Profit margin for the company is -300.00%. Distance from 52-week low is 12.28% and -68.21% from its 52-week high.
The EPS is expected to grow by 41.93% this year
104.0 institutions hold shares in Adc Therapeutics SA (ADCT), with institutional investors hold 77.62% of the company’s shares. The shares outstanding are 96.69M, and float is at 77.58M with Short Float at 5.31%. Institutions hold 61.60% of the Float.
The top institutional shareholder in the company is REDMILE GROUP, LLC with over 15.27 million shares valued at $48.25 million. The investor’s holdings represent 18.4964 of the ADCT Shares outstanding. As of 2024-06-30, the second largest holder is PROSIGHT MANAGEMENT, LP with 9.57 million shares valued at $30.24 million to account for 11.5926 of the shares outstanding. The other top investors are ORBIMED ADVISORS LLC which holds 4.32 million shares representing 5.2292 and valued at over $13.64 million, while BLACKROCK INC. holds 4.306 of the shares totaling 3.55 million with a market value of $11.23 million.
Adc Therapeutics SA (ADCT) Insider Activity
The most recent transaction is an insider purchase by Redmile Group, LLC, the company’s 10% Owner. SEC filings show that Redmile Group, LLC bought 100,000 shares of the company’s common stock on Dec 11 ’24 at a price of $3.04 per share for a total of $0.3 million. Following the purchase, the insider now owns 15.67 million shares.
Adc Therapeutics SA disclosed in a document filed with the SEC on Dec 11 ’24 that Redmile Group, LLC (10% Owner) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Dec 11 ’24 and was made at $3.04 per share for $0.3 million. Following the transaction, the insider now directly holds 13.15 million shares of the ADCT stock.
Still, SEC filings show that on Dec 04 ’24, Redmile Group, LLC (10% Owner) disposed off 25,352 shares at an average price of $2.07 for $52479.0. The insider now directly holds 15,566,731 shares of Adc Therapeutics SA (ADCT).
